Incidental Adrenal Nodules in Patients Without Known Malignancy: Prevalence of Malignancy and Utility of Washout CT for Characterization-A Multiinstitutional Study.

BACKGROUND. Washout CT is commonly used to evaluate indeterminate adrenal nodules, although its diagnostic performance is poorly established in true adrenal incidentalomas. OBJECTIVE. The purpose of this study was to compare, in patients without a known malignancy history, the prevalence of malignancy for incidental adrenal nodules with unenhanced attenuation more than 10 HU that do and do not show absolute washout of 60% or more, thereby determining the diagnostic performance of washout CT for differentiating benign from malignant incidental adrenal nodules. METHODS. This retrospective six-institution study included 299 patients (mean age, 57.3 years; 180 women, 119 men) without known malignancy or suspicion for functioning adrenal tumor who underwent washout CT, which showed a total of 336 adrenal nodules with a short-axis diameter of 1 cm or more, homogeneity, and unenhanced attenuation over 10 HU. The date of the first CT ranged across institutions from November 1, 2003, to January 1, 2017. Washout was determined for all nodules. Reference standard was pathology (n = 54), imaging follow-up (≥ 1 year) (n = 269), or clinical follow-up (≥ 5 years) (n = 13). RESULTS. Prevalence of malignancy among all nodules, nodules less than 4 cm, and nodules 4 cm or more was 1.5% (5/336; 95% CI, 0.5-3.4%), 0.3% (1/317; 95% CI, 0.0-1.7%), and 21.1% (4/19; 95% CI, 6.1-45.6%), respectively. Prevalence of malignancy was not significantly different for nodules smaller than 4 cm with (0% [0/241]; 95% CI, 0.0-1.2%) and without (1.3% [1/76]; 95% CI, 0.0-7.1%) washout of 60% or more (p = .08) or for nodules 4 cm or larger with (16.7% [1/6]; 95% CI, 0.4-64.1%) and without (23.1% [3/13]; 95% CI, 5.0-53.8%) washout of 60% or more (p = .75). Washout of 60% or more was observed in 75.5% (243/322; 95% CI, 70.4-80.1%) of benign nodules (excluding pheochromocytomas), 20.0% (1/5; 95% CI, 0.5-71.6%) of malignant nodules, and 33.3% (3/9; 95% CI, 7.5-70.1%) of pheochromocytomas. For differentiating benign nodules from malignant nodules and pheochromocytomas, washout of 60% or more had 77.5% sensitivity, 70.0% specificity, 98.8% PPV, and 9.2% NPV among nodules smaller than 4 cm. CONCLUSION. Prevalence of malignancy is low among incidental homogeneous adrenal nodules smaller than 4 cm with unenhanced attenuation more than 10 HU and does not significantly differ between those with and without washout of 60% or more; wash-out of 60% or more has suboptimal performance for characterizing nodules as benign. CLINICAL IMPACT. Washout CT has limited utility in evaluating incidental adrenal nodules in patients without known malignancy.

Morphologic features of 211 adrenal masses at initial contrast-enhanced CT: can we differentiate benign from malignant lesions using imaging features alone?

OBJECTIVE: The objective of our study was to determine whether morphologic features of adrenal masses detected at initial contrast-enhanced MDCT can differentiate benign from malignant disease. MATERIALS AND METHODS: Two hundred eleven adrenal masses (1-4 cm) detected during standard contrast-enhanced MDCT with a proven final diagnosis were retrospectively identified in 188 patients through a computer search of CT, PET/CT, and pathology reports. Three authors blinded to the diagnoses independently reviewed the contrast-enhanced MDCT images of the adrenal masses and evaluated their morphologic features: lesion margin (smooth, lobulated, or irregular), density (homogeneous or heterogeneous), and additional features of central low density and enhancing rim. Using these criteria, the readers categorized each mass as probably benign, indeterminate, or suspicious. RESULTS: There were 171 (81%) benign and 40 (19%) malignant adrenal masses. All malignant masses were metastases diagnosed in patients with known extraadrenal malignancy. For individual morphologic features in diagnosing malignancy, irregular margins had 30-33% sensitivity and 95-96% specificity and an enhancing rim had 5-13% sensitivity and 98-99% specificity. None of the imaging features was reliable in predicting benignity. When an adrenal mass was deemed suspicious by a reader, the sensitivities for malignancy ranged from 54% to 74% and specificities from 96% to 97%. Notably, no malignant lesions occurred in patients without a known history of cancer. CONCLUSION: At routine contrast-enhanced MDCT, adrenal masses with irregular margins or a thick enhancing rim are likely to be malignant. Smooth margins and homogeneous density can be seen in both benign and malignant adrenal masses and are insufficient for characterization.

Lexicon for adrenal terms at CT and MRI: a consensus of the Society of Abdominal Radiology adrenal neoplasm disease-focused panel.

PURPOSE: Substantial variation in imaging terms used to describe the adrenal gland and adrenal findings leads to ambiguity and uncertainty in radiology reports and subsequently their understanding by referring clinicians. The purpose of this study was to develop a standardized lexicon to describe adrenal imaging findings at CT and MRI. METHODS: Fourteen members of the Society of Abdominal Radiology adrenal neoplasm disease-focused panel (SAR-DFP) including one endocrine surgeon participated to develop an adrenal lexicon using a modified Delphi process to reach consensus. Five radiologists prepared a preliminary list of 35 imaging terms that was sent to the full group as an online survey (19 general imaging terms, 9 specific to CT, and 7 specific to MRI). In the first round, members voted on terms to be included and proposed definitions; subsequent two rounds were used to achieve consensus on definitions (defined as ≥ 80% agreement). RESULTS: Consensus for inclusion was reached on 33/35 terms with two terms excluded (anterior limb and normal adrenal size measurements). Greater than 80% consensus was reached on the definitions for 15 terms following the first round, with subsequent consensus achieved for the definitions of the remaining 18 terms following two additional rounds. No included term had remaining disagreement. CONCLUSION: Expert consensus produced a standardized lexicon for reporting adrenal findings at CT and MRI. The use of this consensus lexicon should improve radiology report clarity, standardize clinical and research terminology, and reduce uncertainty for referring providers when adrenal findings are present.

Incidental clinically important extraurinary findings at MDCT urography for hematuria evaluation: prevalence in 1209 consecutive examinations.

OBJECTIVE: The purpose of this study is to describe the prevalence and the characteristics of clinically important incidental extraurinary findings detected at MDCT urography performed for hematuria. MATERIALS AND METHODS: A computer search of CT reports using the term "hematuria" identified 1209 reports of patients who had undergone MDCT urography. The results were retrospectively reviewed to determine unsuspected extraurinary findings that are clinically important or potentially important, warranting further imaging studies or medical or surgical intervention. We further categorized these important findings as acute (i.e., requiring immediate medical attention) or nonacute (i.e., requiring further evaluation in a nonurgent manner). By use of our electronic medical records, these findings were correlated to histologic diagnosis, further imaging evaluation, and clinical information. RESULTS: In 82 of 1209 patients (6.8%), 85 clinically important incidental extraurinary findings were identified. Follow-up evaluation was available for 43 of 85 (50.6%) findings by histologic diagnosis (n = 9), imaging evaluation (n = 31), or clinical information (n = 3). There were 11 (0.9%) examinations with acute findings, of which acute inflammation of the gastrointestinal tract and pancreaticobiliary system were the most common. Seventy-two (5.9%) examinations revealed 74 nonacute but important findings. Lung nodules were the most prevalent, followed by intraabdominal aneurysms and cystic ovarian masses. There were five (0.4%) histologically proven malignant neoplasms. CONCLUSION: The prevalence of clinically important incidental extraurinary findings at MDCT urography performed for hematuria was 6.8%.

Hematuria evaluation with MDCT urography: is a contrast-enhanced phase needed when calculi are detected in the unenhanced phase?

OBJECTIVE: The purpose of this study was to assess the added utility of the contrast-enhanced phase of MDCT urography (MDCTU) when urinary tract calculi are detected in the preliminary unenhanced phase. MATERIALS AND METHODS: A computer search of CT reports with the term "hematuria" yielded the records of 1209 patients who had undergone MDCTU. The reports of 286 MDCTU examinations in which urinary tract calculi were detected were identified, and two blinded abdominal radiologists reviewed the images to find a second source of hematuria. The unenhanced images were reviewed first, and the findings were compared with those on the subsequent contrast-enhanced images. The aggregate findings of the 286 examinations in which calculi were present were compared with those of the 923 examinations in which calculi were absent. The follow-up diagnosis was based on histopathologic findings, findings at urologic procedures, or the imaging diagnosis. RESULTS: In 119 of the 1209 patients (10%), 127 lesions other than urinary tract calculi were identified as possible sources of hematuria. Eighty-two lesions were diagnosed in 77 patients (6%) at follow-up evaluation. A second source of hematuria was found in 19 of the 286 examinations (7%) with calculi compared with 58 of the 923 examinations (6%) without calculi (p = 0.828), and contrast was needed to make a specific diagnosis in 16 of the 19 examinations (84%). CONCLUSION: When urinary tract calculi are identified at MDCTU, the rate of detection of other potential causes of hematuria is not different from that in MDCTU examinations without calculi. The contrast-enhanced portion of the MDCTU examination is needed even if calculi are seen because important pathologic changes are diagnosed only after the contrast-enhanced phase.

The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy.

OBJECTIVE: The purpose of our study was to determine the nature and prevalence of adrenal lesions identified on CT in patients with no known malignancy. MATERIALS AND METHODS: A computer search of abdominal CT reports using the term "adrenal" was performed in 65,231 consecutive patients with examinations performed from January 2000 to December 2003. An adrenal mass was identified in 3,307 (5%) patients. Patients with no known malignancy and no suspicion for a hyperfunctioning adrenal mass were further isolated. Nine hundred seventy-three patients with 1,049 adrenal masses fulfilled the study criteria. The nature of each lesion was determined by histopathology; imaging characterization with CT, MRI, or washout; a minimum of 1 year of stability on follow-up imaging; or clinical follow-up of at least 2 years. RESULTS: One thousand forty-nine adrenal masses were characterized with the following methods: histopathology (n = 12), imaging characterization (n = 909), imaging follow-up (n = 87), and clinical follow-up (n = 41). There were 788 adenomas constituting 75% of all lesions. There were 68 myelolipomas (6%), 47 hematomas (4%), and 13 cysts (1%). Three pheochromocytomas (0.3%) and one cortisol-producing adenoma (0.1%) were found incidentally. One hundred twenty-eight lesions (12%) were presumed to be benign by imaging or clinical stability. No malignant adrenal masses were found, even among the 14 patients who later developed malignancy elsewhere. CONCLUSION: In 973 consecutive patients with an incidental adrenal mass and no history of cancer, no malignant lesions were identified. Adenomas (75%) and myelolipomas (6%) were the most common lesions.

The incidental indeterminate adrenal mass on CT (> 10 H) in patients without cancer: is further imaging necessary? Follow-up of 321 consecutive indeterminate adrenal masses.

OBJECTIVE: The objective of our study was to determine whether follow-up imaging evaluation is necessary for incidentally discovered indeterminate adrenal lesions (> 10 H) on CT in patients with no known malignancy. MATERIALS AND METHODS: A computer search of CT reports from January 2000 to December 2003 identified patients with incidentally detected, indeterminate, but benign-appearing adrenal lesions who had no known malignancy and no clinical suspicion of hyperfunctioning adrenal mass. Patients with adrenal masses diagnostic on the initial CT or heterogeneous masses were excluded. Two hundred ninety patients with 321 lesions met the study criteria. Each lesion was determined to be benign or malignant based on histopathology, characterization with diagnostic imaging studies, or a minimum of 1 year of stability on imaging follow-up or 2 years of stability on clinical follow-up. RESULTS: Of the 321 lesions, 318 masses (99.1%) were confirmed to be benign and clinically insignificant. These included three (0.9%) histologically confirmed adenomas, 198 (61.7%) adenomas by imaging characterization, five (1.6%) other benign lesions, 71 (22.1%) masses stable on imaging follow-up, and 41 (12.8%) masses with clinical stability. There were three (0.9%) clinically unsuspected functioning masses: one cortisol-producing adenoma and two pheochromocytomas. There were no metastatic adrenal lesions, even among the 13 patients who subsequently developed malignancy elsewhere. CONCLUSION: All of the incidentally detected adrenal masses with a CT attenuation of > 10 H were benign in patients with no known malignancy. Follow-up imaging to characterize an incidental adrenal mass appears to have a limited role in this patient cohort.

Management of Incidental Adrenal Masses: A White Paper of the ACR Incidental Findings Committee.

The ACR Incidental Findings Committee presents recommendations for managing adrenal masses that are incidentally detected on CT or MRI. These recommendations represent an update to the adrenal component of the JACR 2010 white paper on managing incidental findings in the adrenal glands, kidneys, liver, and pancreas. The Adrenal Subcommittee, constituted by abdominal radiologists and an endocrine surgeon, developed this algorithm. The algorithm draws from published evidence coupled with expert subspecialist opinion and was finalized by a process of iterative consensus. Algorithm branches categorize incidental adrenal masses on the basis of patient characteristics and imaging features. For each specified combination, the algorithm concludes with characterization of benignity or indolence (sufficient to discontinue follow-up) and/or a subsequent management recommendation. The algorithm addresses many, but not all, possible pathologies and clinical scenarios. Our goal is to improve the quality of patient care by providing guidance on how to manage incidentally detected adrenal masses.

Making cost-effectiveness analyses clinically relevant: the effect of provider expertise and biliary disease prevalence on the economic comparison of alternative diagnostic strategies.

RATIONALE AND OBJECTIVES: This study was performed to assess the incremental cost-effectiveness of initial magnetic resonance cholangiopancreatography (MRCP) and initial endoscopic ultrasonography (EUS) compared with initial endoscopic retrograde cholangiopancreatography (ERCP) and to evaluate the effect of MRCP provider expertise on the relative cost-effectiveness of the three methods. MATERIALS AND METHODS: Thirty patients with suspected biliary disease and referred for ERCP were prospectively evaluated with EUS, MRCP, or ERCP within 24 hours of referral, according to institutional review board-approved protocol. Performance characteristics were measured for EUS and MRCP, with ERCP as the reference standard. A decision analysis compared the clinical and economic effects of three diagnostic strategies (ERCP, EUS followed by ERCP [EUS-ERCP], and MRCP followed by ERCP [MRCP-ERCP]) using prospective EUS and MRCP test characteristics and Medicare reimbursements. The added costs per additional correct diagnosis and per additional false-positive finding averted and the rates and costs of ERCP-related complications were calculated for EUS-ERCP and MRCP-ERCP. Two additional MRCP readers reviewed MRCP data to evaluate interobserver variability and estimate provider expertise. Additional economic analyses incorporated these estimates. RESULTS: Compared with initial ERCP, EUS-ERCP demonstrated 72% of biliary abnormalities and reduced ERCP-related complications by 60%; the corresponding percentages for MRCP-ERCP were 48% and 40%. Initial EUS and initial MRCP decreased the number of ERCP procedures performed by 69% and 49%, respectively. Each correct diagnosis made with ERCP that would not have been made with initial EUS or initial MRCP cost an additional 4,875 dollars or 2,580 dollars, respectively. Each false-positive diagnosis averted with initial ERCP that would have been made with EUS-ERCP or MRCP-ERCP cost an additional 9,750 dollars or 1,548 dollars, respectively. The decision model was most sensitive to disease prevalence. As provider expertise increased, the additional cost of an additional correct diagnosis increased for ERCP compared with MRCP-ERCP, with disease prevalence accentuating provider effects. CONCLUSION: Initial EUS and initial MRCP are less costly than initial ERCP, but provider expertise, biliary disease prevalence, and procedural costs influence incremental cost-effectiveness.

Current status of imaging for adrenal gland tumors.

Adrenal glands are common sites of disease involved in a wide spectrum of pathology. Several imaging studies allow accurate diagnosis of adrenal masses, separating inconsequential benign masses from the lesions that require treatment. This article discusses contemporary adrenal imaging techniques, imaging appearance, and the optimal imaging algorithm for the workup of common adrenal masses.

Incidentally discovered adrenal mass.

Adrenal masses are common incidental findings on cross-sectional imaging. Most of these masses are benign, and adenomas are the most common entity. Several imaging studies allow accurate diagnosis of these masses, separating inconsequential benign masses from the lesions that require treatment. This article discusses contemporary adrenal imaging and the optimal algorithm for the workup of incidentally detected adrenal masses.

Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid as an intrabiliary contrast agent: preliminary assessment.

OBJECTIVE: We assessed the added efficacy of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (gadolinium-EOB) in depicting biliary structures compared with T2-weighted MR cholangiopancreatography (T2-MRCP) and measured reviewer preference and willingness-to-pay for the added value of biliary contrast. SUBJECTS AND METHODS: Ten patients prospectively underwent T2-MRCP and gadolinium-EOB-enhanced MR cholangiography (EOB-MRC). Three radiologists reviewed the unpaired, then the paired, examinations, rating biliary visualization using a 5-point scale. The common bile, right and left hepatic ducts, and second-order branches were evaluated. Improved biliary visualization using paired over unpaired tests indicated the added value of contrast media. Kappa values measured interobserver reliability. A regression model controlling for fixed effects due to reviewer and subject correlation quantified improvement in ratings attributable to paired review. RESULTS: Average visualization ratings for unpaired review of EOB-MRC were the following: common bile duct, 3.3; right hepatic duct, 2.7; left hepatic duct, 2.5; second-order branches, 1.4. Average visualization ratings for unpaired review of T2-MCRP were the following: common bile duct, 3.4; right hepatic duct, 1.8; left hepatic duct, 2.2; second-order branches, 0.9. Ratings improved using paired tests over EOB-MRC and T2-MRCP for all structures (p < 0.001) except for T2-MRCP common bile duct ratings (p > 0.05). Agreement was moderate to good except for EOB-MRC common bile duct ratings. Paired review improved ratings (chi(2) < 0.0001) over T2-MRCP alone by 1.05 and over EOB-MRC alone by 0.68. Despite significant improvement, reviewers preferred unpaired T2-MRCP (53%) over unpaired EOB-MRC (17%) or paired tests (30%). Reviewers were willing to pay $25 (median) for gadolinium-EOB. CONCLUSION: Combining T2-MRCP and EOB-MRC significantly improved biliary visualization over each test alone. However, improvement was small, and the perceived added value of gadolinium-EOB was modest.